KR102661217B1 - Functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient - Google Patents

Abstract

The present invention relates to a functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient. The food composition of the present invention includes ① bovine cartilage extract powder containing a large amount of chondroitin, proteoglycan, and type 2 collagen, which can help improve arthritis, ② Angelica root, Astragalus root, licorice root, peony root, and Astragalus root. It contains a mixed plant extract composed of rhizomes, ③ boswellia extract powder containing about 65% of boswellic acid, and has excellent antioxidant, anti-inflammatory, cartilage strengthening, and arthritis improving effects.

Description

Functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient}

The present invention relates to a functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient.

Joints are composed of cartilage, joint capsule, synovial membrane, ligaments, tendons, and muscles to allow smooth movement between bones, and serve to absorb shock that occurs during movement. Arthritis is inflammation of the joints due to various causes, and the most common symptom is joint pain. There are several types of arthritis depending on the site or cause of the disease, and it is broadly classified into osteoarthritis (degenerative arthritis) and rheumatoid arthritis.

Osteoarthritis (degenerative arthritis) is a disease in which localized degenerative changes occur as joint cartilage wears away. Excessive use of cartilage over a long period of time such as repetitive work or exercise, excessive strain on the joint due to obesity, joint trauma, etc. may be the causes, and rheumatoid arthritis is characterized by a continuous inflammatory response in the joint synovium. It is a chronic inflammatory systemic disease. Although the exact cause is not known, the hypothesis is that it is an immune response that produces autoantibodies and causes an inflammatory response when people with a genetic predisposition are exposed to environmental factors such as smoking or infectious agents such as periodontitis.

Inflammatory arthritis also generally refers to joint diseases in which the immune system and/or some other mechanism causes inflammation in the joints, for example, some of the more common types of inflammatory arthritis include rheumatoid arthritis, gout, and psoriatic arthritis (skin conditions). associated with psoriasis), reactive arthritis, viral or post-viral arthritis (occurs after an infection), and spinal arthritis that affects the spine as well as the joints. Recently, research to discover arthritis-related functional foods and new natural products from natural products that have been used as traditional medicine or folk remedies has been receiving worldwide attention, especially in developed countries such as the United States, Europe, and Japan.

The present inventors developed a bovine cartilage extract containing a large amount of chondroitin, proteoglycan, and type 2 collagen, which can help improve arthritis, and mixed it with the optimal mixing ratio of other ingredients that can help improve arthritis. The composition development was completed.

10-0586809

The purpose of the present invention is to provide a method for producing a functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient.

Another object of the present invention is to provide a functional food composition for strengthening cartilage and improving arthritis containing chondroitin prepared by the above method as an active ingredient.

In order to achieve the above object, the present invention uses purified water, mixed plant extract, bovine cartilage extract, N-acetylglucosamine, bromelain, green lipped mussel extract, boswellia extract, turmeric extract, calcium citrate, and magnesium gluconate. A food composition for strengthening cartilage and improving arthritis containing zinc oxide, vitamin D and E mixed preparation, vitamin K mixed preparation, selenium, manganese sulfate, fructooligosaccharide, anhydrous citric acid, enzyme-treated stevia, and Daebohyang flavoring as active ingredients. to provide.

In one embodiment of the present invention, the "mixed plant extract" may be a mixture of Angelica root, Astragalus root, Licorice root, Peony root, and Astragalus rhizome extracts in the same mixing ratio, but is not limited thereto.

In one embodiment of the present invention, the “food composition” contains 26 to 30% by weight of purified water, 16 to 20% by weight of mixed plant extract, 13 to 17% by weight of bovine cartilage extract, 0.1 to 2% by weight of N-acetylglucosamine, and bromide. Melanin 0.5~3% by weight, green lipped mussel extract 0.5~4% by weight, boswellia extract 1~5% by weight, turmeric extract 1~5% by weight, calcium citrate 1~5% by weight, magnesium gluconate 1~5% Weight%, zinc oxide 0.05~0.3% by weight, vitamin D and E mixture 0.02~0.06% by weight, vitamin K mixture 0.01~0.04% by weight, selenium 0.06~0.1% by weight, manganese sulfate 0.1~0.14% by weight, fructo It may contain 13 to 17% by weight of oligosaccharides, 0.5 to 4% by weight of anhydrous citric acid, 1 to 5% by weight of enzyme-treated stevia, and 1 to 5% by weight of Daebohyang flavoring, and preferably 27 to 29% by weight of purified water and plants. Mixed extract 17-19% by weight, bovine cartilage extract 14-16% by weight, N-acetylglucosamine 0.5-1.5% by weight, bromelain 1-2% by weight, green lipped mussel extract 1-3% by weight, boswellia extract 2~4% by weight, turmeric extract 2~3% by weight, calcium citrate 2~3% by weight, magnesium gluconate 2~3% by weight, zinc oxide 0.1~0.2% by weight, vitamin D and E mixture 0.03~0.05% by weight. , Vitamin K mixture 0.015-0.03% by weight, selenium 0.07-0.09% by weight, manganese sulfate 0.11-0.13% by weight, fructooligosaccharide 14-16% by weight, anhydrous citric acid 1-3% by weight, enzyme-treated stevia 2-4% % and Daebohyang fragrance may be included in 2 to 4% by weight, but are not limited to this.

In one embodiment of the present invention, the “food composition” may have antioxidant and anti-inflammatory effects, but is not limited thereto.

In addition, the present invention includes purified water, mixed plant extract, bovine cartilage extract, N-acetylglucosamine, bromelain, green lipped mussel extract, boswellia extract, turmeric extract, calcium citrate, magnesium gluconate, zinc oxide, vitamin D and We provide a health functional food composition for strengthening cartilage and improving arthritis containing E mixed preparation, vitamin K mixed preparation, selenium, manganese sulfate, fructo-oligosaccharide, anhydrous citric acid, enzyme-treated stevia, and Daebohyang flavoring as active ingredients.

The present invention relates to a functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient. The food composition of the present invention is composed of ① bovine cartilage extract, which contains a large amount of chondroitin, proteoglycan, and type 2 collagen, which can help improve arthritis, ② Angelica root, Astragalus root, licorice root, peony root, and Astragalus root. It contains a mixed plant extract composed of stems, ③ Boswellia extract, which contains about 65% of boswellic acid, and has excellent antioxidant, anti-inflammatory, cartilage strengthening, and arthritis improving effects.

Figure 1 is a diagram showing key components of bovine cartilage extract in one embodiment of the present invention.
Figure 2 is a diagram showing the key components of Boswellia extract in one embodiment of the present invention.

Hereinafter, the present invention will be described in detail through embodiments of the present invention with reference to the attached drawings. However, the following implementation examples are provided as examples of the present invention, and if it is judged that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted. , the present invention is not limited thereby. The present invention is capable of various modifications and applications within the description of the patent claims described below and the scope of equivalents interpreted therefrom.

In addition, terminology used in this specification is a term used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator or the customs of the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part is said to “include” a certain element, this means that it may further include other elements rather than excluding other elements, unless specifically stated to the contrary.

Throughout this specification, '%' used to indicate the concentration of a specific substance means (w/w) % for solid/solid, (w/v) % for solid/liquid, and Liquid/Liquid is (v/v) %.

In one aspect, the present invention provides a functional food composition for strengthening cartilage and improving arthritis containing chondroitin as an active ingredient.

In order to provide the chondroitin of the present invention as described above, bovine cartilage extract is provided, and a mixed plant extract consisting of Angelica root, Astragalus root, Licorice root, Peony root, and Astragalus rhizome extract, green-lipped mussel extract, and Boswellia extract. and turmeric extract.

At this time, the extract according to the present invention can be obtained by extraction and separation from domestic natural raw materials using extraction and separation methods known in the art, and "extract" as defined in the present invention can be extracted and separated using an appropriate solvent. It is extracted from cartilage, angelica root, astragalus root, licorice root, peony root, Astragalus rhizome, green-lipped mussel, boswellia and turmeric, for example, crude extract, polar solvent soluble extract or non-polar solvent soluble extract. Includes. As an appropriate solvent for preparing extracts from the above bovine cartilage, Angelica root, Astragalus root, Licorice root, Peony root, Astragalus rhizome, green-lipped mussel, Boswellia and turmeric, any organic solvent acceptable in food science can be used. Any solvent may be used, and water or an organic solvent may be used, but are not limited thereto, for example, purified water, methanol, ethanol, propanol, isopropanol, butanol, etc. Alcohols having 1 to 4 carbon atoms, including acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclo Various solvents such as hexane (cyclohexane) can be used individually or in combination. As an extraction method, any one of the following methods can be selected and used: hot water extraction, cold needle extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression. In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method.

There is no limitation to the method for producing the extract in the present invention, and any known method can be used. For example, the extract used in the present invention can be prepared in powder form from the primary extract extracted by the above-described hot water extraction or solvent extraction method by additional processes such as reduced pressure distillation and freeze-drying or spray drying. In addition, the primary extract was further purified into fractions using various chromatographies such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. You can also get it. Therefore, in the present invention, extract is a concept that includes all extracts, fractions, and purifications obtained at each stage of extraction, fractionation, or purification, as well as their dilutions, concentrates, or dried products.

In one aspect, the present invention can provide a food or health functional food composition for strengthening cartilage and improving arthritis.

In addition to containing the extract as an active ingredient, the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like a typical food composition.

Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-described flavoring agents include natural flavoring agents (thaumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, health supplements, etc. There is.

In addition, the food composition contains, in addition to the extract as an active ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and fillers (cheese, chocolate, etc.), pectic acid and its salts, and alginic acid. and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.

The health functional food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. In the present invention, 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and has It means taking it for the purpose of controlling nutrients or obtaining useful health effects such as physiological effects. The health functional food of the present invention may contain common food additives, and its suitability as a food additive is determined in accordance with the general provisions and general test methods of the food additive code approved by the Food and Drug Administration, unless otherwise specified. Judgment is made according to specifications and standards. Items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, high-quality pigment, and guar gum; Examples include mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations. For example, the health functional food in the form of a tablet is made by granulating a mixture of the active ingredient of the present invention with excipients, binders, disintegrants and other additives in a conventional manner, and then adding a lubricant and compression molding, or The mixture can be directly compression molded. In addition, the health functional food in the form of tablets may contain flavoring agents, etc., if necessary. Among capsule-type health functional foods, hard capsules can be manufactured by filling a regular hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules can be prepared by mixing the active ingredient of the present invention with additives such as excipients. It can be manufactured by filling the mixture with a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary. The health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention and excipients, binders, disintegrants, etc., using a known method. If necessary, it can be coated with white sugar or other coating agents. Alternatively, the surface can be coated with substances such as starch or talc. Health functional food in the form of granules can be manufactured into granules by mixing a mixture of excipients, binders, disintegrants, etc. of the active ingredients of the present invention by a known method, and may contain flavoring agents, flavoring agents, etc., if necessary. You can.

In one aspect, the present invention can provide a pharmaceutical composition for preventing or treating arthritis.

The pharmaceutical composition of the present invention may further include adjuvants in addition to the active ingredients. The auxiliary agent may be any one known in the art without limitation, but its functionality may be increased by further including, for example, Freund's complete auxiliary agent or incomplete auxiliary agent.

The pharmaceutical composition according to the present invention can be prepared by incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, pharmaceutically acceptable carriers include carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, Examples include calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions according to conventional methods. .

When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain the active ingredient plus at least one excipient, such as starch, calcium carbonate, sucrose, lactose, and gelatin. It can be prepared by mixing etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used diluents such as water and liquid paraffin, they contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. You can. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, tween 61, cacao, laurel, glycerogelatin, etc. can be used.

The pharmaceutical composition according to the present invention can be administered to an individual through various routes. All modes of administration are contemplated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.

The dosage of the pharmaceutical composition according to the present invention is selected taking into account the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the target, and is preferably included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg/ml. If the concentration is less than 0.01 ㎍/ml, pharmaceutical activity may not appear, and if it exceeds 5,000 ㎍/ml, it may be toxic to the human body.

The pharmaceutical composition may be formulated into various oral or parenteral dosage forms.

Dosage forms for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These dosage forms contain diluents (e.g. lactose, dextrose, water) in addition to the active ingredient. crose, mannitol, sorbitol, cellulose and/or glycine), lubricants (e.g. silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol). Additionally, the tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid. or disintegrants such as sodium salts thereof or effervescent mixtures and/or absorbents, colorants, flavoring and sweetening agents. The formulation can be prepared by conventional mixing, granulating or coating methods.

In addition, representative formulations for parenteral administration are injectable formulations, and solvents for injectable formulations include water, Ringer's solution, isotonic saline solution, or suspension. The sterile fixed oil of the injectable preparation can be used as a solvent or suspending medium, and any non-irritating fixed oil, including mono- and di-glycerides, can be used for this purpose.

Additionally, the injectable preparation may use fatty acids such as oleic acid.

Hereinafter, the present invention will be described in more detail through examples. However, the above examples and experimental examples are presented as examples of the present invention, and if it is judged that detailed descriptions of techniques or configurations well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed descriptions are omitted. It can be done, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the description of the claims described below and the scope of equivalents interpreted therefrom.

<Manufacturing example> Method for producing functional composition

A total of 19 raw materials were mixed to prepare the functional composition of the present invention. The raw materials and mixing ratio shown in Table 1 below correspond to the mixing ratio optimized through various experiments.

turn Material name usage
(mg) Mixing ratio
(weight%) etc One Purified water 2859 28.59 2 Mixed plant extract 1800 18 Mix equal weight of angelica root, astragalus root, licorice root, peony root and Astragalus rhizome.
- Angelica gigas root: Promotes blood flow in coronary arteries and contains decusin, a powerful anti-inflammatory ingredient
- Astragalus membranaceus : Contains saponins and flavonoids with powerful antioxidant and anti-inflammatory properties
- Licorice root ( Clycyrrhiza uralensis ): An ingredient that contains liquiritigenin and liquiritin flavonoids and has muscle spasm relieving properties
- Peony root ( Paeonia lactiflora ): An ingredient that contains paeonin and has properties that prevent muscle pain
- Cnidium officinale : Contains saponin and carbonic acid and has anti-inflammatory and joint lubricating properties. 3 Bovine cartilage extract 1500 15 Contains 375 mg of chondroitin sulfate, 30 mg of proteoglycan, and 150 mg of type 2 collagen per 1500 mg of bovine cartilage extract. 4 N-Acetylglucosamine (NAG) 100 One A known ingredient that constitutes cell-to-cell bonds, mucous membranes, and joint synovial fluid. 5 Bromelain 150 1.5 Enzyme extracted from pineapple 6 Green lipped mussel extract ( Perna canaliculus ) 200 2 The secret to health among Maoris raised in New Zealand 7 Boswellia Extract 300 3 Contains 65% boswellic acid and is called the pearl of the desert. 8 Turmeric root extract 250 2.5 Curry ingredients help relieve hangovers and internal fatigue 9 Calcium citrate 250 2.5 It is a major component of bone and has a higher absorption rate in the body compared to regular calcium. 10 Magnesium Gluconate 250 2.5 An ingredient that plays an important role in the normal function of muscles and has a higher bioavailability compared to regular magnesium. 11 zinc oxide 15 0.15 Ingredients necessary for normal immune function and cell division 12 Vitamin D, E mixed preparation 4 0.04 Maintains constant absorption and concentration of calcium 13 Vitamin K mixed preparation 2 0.02 Fat-soluble vitamin that helps bone structure and blood clotting 14 Selenium 8 0.08 Antioxidant ingredient that removes free radicals 15 manganese sulfate 12 0.12 Essential minerals needed for bone formation, energy utilization, and cell protection 16 Fructooligosaccharide 1500 15 prebiotics 17 Anhydrous citric acid 200 2 Effective in relieving fatigue and discharging waste products from the skin 18 Enzyme-treated stevia 300 3 It is obtained by adding glucose to stevia extract using α-glucosyltransferase, etc., and its components include α-glucosylstevioside, etc. 19 Daebohyang 300 3 Spices Sum 10000 100

A liquid mixed composition was prepared by mixing the raw materials in Table 1 at the indicated weight. The reason it is manufactured as a liquid composition is because the liquid is absorbed directly into the blood without going through a metabolic process and is absorbed faster than the tablet or powder form. Additionally, the composition of the present invention is set to be consumed one packet per day before or after a meal (10,000 mg per packet, approximately 20 kcal).

Table 2 below shows comparative examples prepared together with Table 1 above. At this time, the experimental groups were set to have a total content of 10,000 mg.

turn Raw material name Usage (mg) Example 1 Example 2 Example 3 Comparative Example 1 Comparative example 2 Comparative Example 3 Comparative example 4 Comparative Example 5 One Purified water 2859 2859 2859 2859 2859 2859 2859 2859 2 Mixed plant extract 1800 0 3300 Changing the plant extracts each consists of 1800 1800 1800 1800 1800 3 Bovine cartilage extract 1500 3300 0 1500 1500 1500 1500 1500 4 N-Acetylglucosamine (NAG) 100 100 100 100 100 100 100 100 5 Bromelain 150 150 150 150 150 150 150 150 6 Green Lipped Mussel Extract 200 200 200 200 200 200 200 200 7 Boswellia Extract 300 300 300 300 300 300 300 300 8 Turmeric Extract 250 250 250 250 250 250 250 250 9 Calcium citrate 250 250 250 250 250 250 250 250 10 Magnesium Gluconate 250 250 250 250 250 250 250 250 11 zinc oxide 15 15 15 15 15 15 15 15 12 Vitamin D, E mixed preparation 4 4 4 4 4 4 4 4 13 Vitamin K mixed preparation 2 2 2 2 2 2 2 2 14 Selenium 8 8 8 8 8 8 8 8 15 manganese sulfate 12 12 12 12 12 12 12 12 16 Fructooligosaccharide 1500 1500 1500 1500 1500 1500 1500 1500 17 Anhydrous citric acid 200 200 200 200 200 200 200 200 18 Enzyme-treated stevia 300 300 300 300 300 300 300 300 19 Daebohyang 300 300 300 300 300 300 300 300 Total (mg) 10000 10000 10000 10000 10000 10000 10000 10000

In Table 2, Examples 2 and 3 used only the mixed plant extract or bovine cartilage extract. In addition, in Comparative Examples 1 to 5, the extracts constituting the mixed plant extract were prepared differently. The configuration table for this is shown in Table 3 below.

Usage (mg) Example 1 Comparative Example 1 Comparative example 2 Comparative Example 3 Comparative example 4 Comparative Example 5 Angelica Root 360 - 450 450 600 - Astragalus root 360 450 - 450 600 - Licorice root 360 450 450 - 600 600 peony root 360 450 450 450 - 600 Cheongung rhizome 360 450 450 450 - 600 Sum 1800 1800 1800 1800 1800 1800

<Experimental Example 1> Antioxidant efficacy test of functional composition

1-1. DPPH radical scavenging ability

To evaluate the antioxidant effect of the compositions of Examples 1 to 3 and Comparative Examples 1 to 5 prepared in the <Preparation Example>, DPPH assay was performed. At this time, ascorbic acid (AA) was used as the positive control group. DPPH was dissolved in ethyl alcohol at a concentration of 0.2 mM, 100 μl of the DPPH solution was reacted with 100 μl of each sample for 20 minutes, and the absorbance (OD) was measured at 517 nm using a spectrophotometer (microplate reader). Additionally, the DPPH radical scavenging ability was calculated using Equation 1 below, and the results are shown in Table 4 below.

[Equation 1]

DPPH inhibition(%) = [1-(Abssample/Abscontrol)] × 100

sample DPPH radical scavenging ability (%) Example 1 88% Example 2 58% Example 3 71% Comparative Example 1 66% Comparative Example 2 61% Comparative Example 3 58% Comparative Example 4 62% Comparative Example 5 47% Ascorbic acid (positive control) 78%

As can be seen in Table 4, the composition of Example 2, in which the content ratio of the bovine cartilage extract was increased except for the mixed plant extract, had a very low DPPH radical scavenging ability, and the content ratio of the mixed plant extract except for the bovine cartilage extract was It was confirmed that the improved composition of Example 3 had a somewhat low DPPH radical scavenging ability. In addition, it was confirmed that Comparative Examples 1 to 3, excluding one of the components of the mixed plant extract, and Comparative Examples 4 and 5, excluding two of the components, had very low DPPH radical scavenging ability.

1-2. ABTS radical scavenging ability

To evaluate the antioxidant effect of the compositions of Examples 1 to 3 and Comparative Examples 1 to 5 prepared in the <Preparation Example>, ABTS assay was performed. At this time, ascorbic acid (AA) was used as the positive control group. Prepare ABTS solution by mixing 7mM ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) and 2.45mM potassium persulfate in a 1:1 ratio and storing in the dark for 16 hours. did. The prepared ABTS solution was diluted in 50% (v/v) methanol and adjusted to an absorbance of 0.7 ± 0.02 at 745 nm. After reacting 180 μl of ABTS solution and 20 μl of each sample for 10 minutes, the absorbance was measured at 745 nm with a microplate reader. ABTS radical scavenging ability was calculated using Equation 2 below, and the results are shown in Table 5 below.

[Equation 2]

ABTS inhibition(%) = [1-(Abssample/Abscontrol)] × 100

sample ABTS radical scavenging ability (%) Example 1 83% Example 2 62% Example 3 69% Comparative Example 1 52% Comparative Example 2 53% Comparative Example 3 59% Comparative Example 4 61% Comparative Example 5 48% Ascorbic acid (positive control) 82%

As can be seen in Table 5, the composition of Example 2, in which the content ratio of the bovine cartilage extract was increased except for the mixed plant extract, had a very low ABTS radical scavenging ability, and the content ratio of the mixed plant extract except for the bovine cartilage extract was It was confirmed that the improved composition of Example 3 had a somewhat low ABTS radical scavenging ability. In addition, it was confirmed that Comparative Examples 1 to 3, excluding one of the components of the mixed plant extract, and Comparative Examples 4 and 5, excluding two of the components, had very low ABTS radical scavenging ability.

<Experimental Example 2> Anti-inflammatory efficacy test in cartilage cells

SW1353 In human chondrocytes, the content of prostaglandin E2 (PGE2), an inflammatory mediator, changes in response to treatment with the composition of the present invention, and MMPs (MMP-1 and MMP-13), cartilage matrix degrading enzymes, are activated by an increase in inflammatory cytokines. Inhibition and changes in the content of glycosaminoglycan (GAG), a decomposition product of cartilage proteoglycan, were confirmed. At this time, SW1353 human chondrocytes were cultured using a culture medium supplemented with 10% FBS in DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12), treated with 50 to 100 μl of the composition, and cultured for 2 hours. Afterwards, 10 μg/ml of interleukin-1 beta (IL-1β) was treated for 24 hours.

2-1. Ability to inhibit prostaglandin E2 (PGE2) production induced by inflammatory cytokines

In order to evaluate the anti-inflammatory effect of the composition of the present invention, an ELISA kit (R&D Systems) was used to measure the effect of inhibiting the production of PGE2, an inflammatory mediator. The results are shown in Table 6 below.

sample PGE2 (pg/ml) Control 50±5.2 Interleukin-1 beta (IL-1β) treatment 252 ± 12.4 Example 1 (50㎕) 62 ± 10.5 Example 1 (100㎕) 51 ± 11.2 Example 2 (50㎕) 201 ± 9.8 Example 2 (100㎕) 112 ± 14.6 Example 3 (50㎕) 182 ± 12.5 Example 3 (100㎕) 95±10.6

As can be seen in Table 6, PGE2 production was very highly increased in chondrocytes by treatment with IL-1β, and the most significant decrease in PGE2 production was confirmed in cells pretreated with the composition of Example 1 of the present invention.

2-2. Ability to suppress MMP-1 and MMP-13 expression levels mediated by inflammatory cytokines

The extracellular matrix (ECM) that constitutes cartilage tissue is decomposed due to the activation and synthesis of MMP-1 and MMP-13 among MMPs due to the secretion of the inflammatory cytokine interleukin-1 beta (IL-1β). An ELISA kit (R&D Systems) was used to confirm whether the composition of the present invention affects the expression of MMPs. The results are shown in Tables 7 and 8 below.

sample MMP-1 (ng/ml) Control 1 ± 0.1 Interleukin-1 beta (IL-1β) treatment 25±0.4 Example 1 (50㎕) 17±0.5 Example 1 (100㎕) 9 ± 0.2 Example 2 (50㎕) 21 ± 1.1 Example 2 (100㎕) 16±0.8 Example 3 (50㎕) 20±0.5 Example 3 (100㎕) 15±1.6

sample MMP-13 (ng/ml) Control 1 ± 0.1 Interleukin-1 beta (IL-1β) treatment 12±0.2 Example 1 (50㎕) 8 ± 0.5 Example 1 (100㎕) 4±0.9 Example 2 (50㎕) 9 ± 1.2 Example 2 (100㎕) 7 ± 1.0 Example 3 (50㎕) 10±0.5 Example 3 (100㎕) 9 ± 0.2

As can be seen in Tables 7 and 8 above, the expression levels of MMP-1 and MMP-13 were very highly increased in the culture supernatant of chondrocytes treated with IL-1β, but in cells pretreated with the composition of Example 1 of the present invention, IL The expression levels of MMP-1 and MMP-13 were most significantly decreased by -1β in a concentration-dependent manner.

2-3. Glycosaminoglycan (GAG) content inhibition ability

Glycosaminoglycan (GAG) is an essential component of cartilage tissue and is a substance produced by the decomposition of proteoglycan. Therefore, in order to determine whether the composition of the present invention affects the content of glycosaminoglycan, after treating IL-1β for 24 hours, the culture supernatant was reacted with blyscan dye and the absorbance was measured at 656 nm to measure the amount of GAG. is shown in Table 9 below.

sample GAGs (ug/ml) Control 0.4 ± 0.1 Interleukin-1 beta (IL-1β) treatment 0.7 ± 0.1 Example 1 (50㎕) 0.6 ± 0.1 Example 1 (100㎕) 0.4 ± 0.0 Example 2 (50㎕) 0.8 ± 0.1 Example 2 (100㎕) 0.7 ± 0.2 Example 3 (50㎕) 0.6 ± 0.0 Example 3 (100㎕) 0.6 ± 0.1

As a result, it was confirmed that the content of glycosaminoglycan (GAG), which increased by promoting cartilage degradation due to IL-1β, was most significantly reduced by treatment with the composition of Example 1 of the present invention.

As seen above, specific embodiments of the present invention have been described in detail, but those skilled in the art who understand the spirit of the present invention may add, change, delete, etc. other components within the scope of the same spirit, thereby creating other regressive inventions. However, other embodiments that are included within the scope of the present invention can be easily proposed. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention is indicated by the scope of the claims described below rather than the detailed description above, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts are included in the scope of the present invention. It should be interpreted as

Claims (5)

Purified water 27~29% by weight, mixed plant extract 17~19% by weight, bovine cartilage extract 14~16% by weight, N-acetylglucosamine 0.5~1.5% by weight, bromelain 1~2% by weight, green lipped mussel extract 1~ 3% by weight, boswellia extract 2~4% by weight, turmeric extract 2~3% by weight, calcium citrate 2~3% by weight, magnesium gluconate 2~3% by weight, zinc oxide 0.1~0.2% by weight, vitamin D and E mixed preparation 0.03~0.05% by weight, Vitamin K mixed preparation 0.015~0.03% by weight, selenium 0.07~0.09% by weight, manganese sulfate 0.11~0.13% by weight, fructooligosaccharide 14~16% by weight, anhydrous citric acid 1~3% by weight , in a food composition for improving arthritis containing 2 to 4% by weight of enzyme-treated stevia and 2 to 4% by weight of flavoring as active ingredients,
The mixed plant extract is a food composition for improving arthritis, which is a mixture of Angelica root, Astragalus root, Licorice root, Peony root, and Astragalus rhizome extract.
delete delete In paragraph 1:
A food composition for improving arthritis, characterized in that the food composition has antioxidant and anti-inflammatory effects.
Purified water 27~29% by weight, mixed plant extract 17~19% by weight, bovine cartilage extract 14~16% by weight, N-acetylglucosamine 0.5~1.5% by weight, bromelain 1~2% by weight, green lipped mussel extract 1~ 3% by weight, boswellia extract 2~4% by weight, turmeric extract 2~3% by weight, calcium citrate 2~3% by weight, magnesium gluconate 2~3% by weight, zinc oxide 0.1~0.2% by weight, vitamin D and E mixed preparation 0.03~0.05% by weight, Vitamin K mixed preparation 0.015~0.03% by weight, selenium 0.07~0.09% by weight, manganese sulfate 0.11~0.13% by weight, fructooligosaccharide 14~16% by weight, anhydrous citric acid 1~3% by weight , in a health functional food composition for improving arthritis containing 2 to 4% by weight of enzyme-treated stevia and 2 to 4% by weight of flavoring as active ingredients,
The mixed plant extract is a health functional food composition for improving arthritis, which is a mixture of Angelica root, Astragalus root, Licorice root, Peony root, and Astragalus rhizome extract.